ArticleAnnals of the rheumatic diseases2013
Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis.
Article in Annals of the rheumatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Immature forms of low density granulocytes are increased in acute myeloid leukemia and myelodysplastic syndromes.Scientific reports · 2025Article
- A strategy to design protein-based antagonists against type I cytokine receptors.PLoS biology · 2024Article
- Profiles of cytokines in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Frontiers in immunology · 2024Article
- Animal models for anti-neutrophil cytoplasmic antibody-associated vasculitis: Are current models good enough?Animal models and experimental medicine · 2023Review
- Proliferative glomerulonephritis with monoclonal IgG deposits triggered by Filgrastim in a patient with multiple myeloma.Journal of nephrology · 2023Article
- Phosphatidylinositol 3-Kinase δ Deficiency Protects From Antimyeloperoxidase Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective.Kidney international · 2023Article
- G-CSF-induced ANCA associated glomerulonephritis in the presence of silent membranous "full house nephropathy" in an altruistic bone marrow donor.Renal failure · 2022Article
- Experimentally Induced Anti-Myeloperoxidase Vasculitis Is Not Attenuated in Factor B or VISTA Deficient Mice.Glomerular diseases · 2022Article
- Acute glomerulonephritis in a hematopoietic blood stem cell donor.Clinical nephrology. Case studies · 2021Article
- Immunopathogenesis of ANCA-Associated Vasculitis.International journal of molecular sciences · 2020Review
- Coaxing Anti-Inflammatory Granulocytes to Prevent Ischemic Kidney Injury: A Fine Balance.Journal of the American Society of Nephrology : JASN · 2020Article
- Animal Models of ANCA Associated Vasculitis.Frontiers in immunology · 2020Review
- Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies.Frontiers in immunology · 2019Article
- Re-Examining Neutrophil Participation in GN.Journal of the American Society of Nephrology : JASN · 2017Review
- Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.The Journal of pathology · 2016Article
- An update on drug-induced arthritis.Rheumatology international · 2016Review
- The role of neutrophils and NETosis in autoimmune and renal diseases.Nature reviews. Nephrology · 2016Review
- Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.Journal of the American Society of Nephrology : JASN · 2016Article
- Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis.The Journal of clinical investigation · 2015Article
Corrections and comments
- Erratum issuedCorrection:2022
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesGranulocyte colony stimulating factor (GCSF) is important in mobilising neutrophils from the bone marrow but also has a range of proinflammatory effects. We therefore decided to investigate the role of GCSF in antineutrophil cytoplasmic antibody (ANCA) vasculitis.
methodsWe measured GCSF levels in the serum of 38 patients with active ANCA vasculitis compared with 31 age-matched controls, and assessed the effect of GCSF priming on the response of human neutrophils to ANCA. We also examined the effect of exogenous GCSF administration in a murine model of antimyeloperoxidase (anti-MPO) vasculitis, and the effect of GCSF on murine neutrophil activation.
resultsThe serum levels of GCSF in patients with active ANCA vasculitis were significantly higher than those of age matched healthy controls (mean 38.04 vs 18.35 pg/ml, p<0.001). Furthermore, we demonstrated that GCSF primed human neutrophils in vitro for a respiratory burst in response to anti-MPO ANCA. In an anti-MPO antibody transfer model, mice given GCSF had more crescents (mean 29.1% vs 5.8% per glomerular cross section, p<0.05), more macrophages (mean 3.2 vs 1.2 per glomerular cross-section, p<0.01), higher serum creatines (mean 13.6 vs 8.3 μmol/l, p<0.05) and more haematuria (p<0.05) compared with controls. In vivo administration of GCSF with lipopolysaccharide (LPS), but not LPS alone, led to upregulation of CD11c on murine neutrophils.
conclusionsThese data suggest that GCSF, which is raised in patient serum, may play an important role in exacerbating disease in ANCA vasculitis. In addition, GCSF therapy for neutropenia should be used with caution in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.